Yidong Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yidong Yang has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Bin Wu
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
17 shared publications Hongsheng Yu
Department of Gastroenterology The Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou People's Republic of China
10 shared publicationsBilan Yang
Department of Gastroenterology Guangzhou Eighth People's Hospital, Guangzhou Medical University Guangzhou China
9 shared publicationsHao Jiang
Department of Gastroenterology The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
9 shared publicationsMingkai Li
Department of Gastroenterology, Shenzhen Hospital Southern Medical University Shenzhen People's Republic of China
8 shared publicationsYiming Lei
Department of Gastroenterology The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
8 shared publications
Latest Publications
- 14 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70866
ALPS ‐ HCC Score: A Dynamic Liver Stiffness Measurement‐Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma
Background & Aims: Existing hepatocellular carcinoma (HCC) risk scores specific to chronic hepatitis B (CHB) mostly rely solely on baseline indicators, limiting their applicability in clinical practice. By incorporating dynamic and static indicators, this study aimed to address this limitation by developing a machine learning (ML) model for HCC prediction in patients with CHB and compensated advanced chronic liver disease (cACLD). Methods: ML models were trained to predict HCC in 1 272 patients with CHB and cACLD, who underwent at least 2 measurements from different centres and were further tested with external cohorts ( n = 601). The first and last liver stiffness measurements were defined as the baseline and follow‐up values, respectively. Results: A total of 1 873 individuals with CHB and cACLD were included, with 192 patients (10.3%) developing HCC after a median of 30.7 months. Based on LASSO logistic regression, baseline age, baseline albumin concentration, follow‐up albumin concentration, follow‐up platelet count, and change in the liver stiffness measurement (∆LSM) were selected, with ∆LSM identified as the most important indicator. Developed using XGBoost, the ALPS‐HCC score achieved the highest integrated AUROC (0.852), Harrell's C‐index (0.852), and F1 score (0.944), and performed significantly better than existing HCC risk scores. Based on these results, our risk stratification performed well in terms of prognosis in the validation cohort, including the identification of low‐risk ( n = 250; reference), intermediate‐risk ( n = 91; hazard ratio [HR] = 5.25), and high‐risk ( n = 41; HR = 24.47) groups. Conclusions: ALPS‐HCC score provides robust predictive power and screening capability for predicting HCC risk in patients with CHB and cACLD.
- 14 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70866
ALPS ‐ HCC Score: A Dynamic Liver Stiffness Measurement‐Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma
Background & Aims: Existing hepatocellular carcinoma (HCC) risk scores specific to chronic hepatitis B (CHB) mostly rely solely on baseline indicators, limiting their applicability in clinical practice. By incorporating dynamic and static indicators, this study aimed to address this limitation by developing a machine learning (ML) model for HCC prediction in patients with CHB and compensated advanced chronic liver disease (cACLD). Methods: ML models were trained to predict HCC in 1 272 patients with CHB and cACLD, who underwent at least 2 measurements from different centres and were further tested with external cohorts ( n = 601). The first and last liver stiffness measurements were defined as the baseline and follow‐up values, respectively. Results: A total of 1 873 individuals with CHB and cACLD were included, with 192 patients (10.3%) developing HCC after a median of 30.7 months. Based on LASSO logistic regression, baseline age, baseline albumin concentration, follow‐up albumin concentration, follow‐up platelet count, and change in the liver stiffness measurement (∆LSM) were selected, with ∆LSM identified as the most important indicator. Developed using XGBoost, the ALPS‐HCC score achieved the highest integrated AUROC (0.852), Harrell's C‐index (0.852), and F1 score (0.944), and performed significantly better than existing HCC risk scores. Based on these results, our risk stratification performed well in terms of prognosis in the validation cohort, including the identification of low‐risk ( n = 250; reference), intermediate‐risk ( n = 91; hazard ratio [HR] = 5.25), and high‐risk ( n = 41; HR = 24.47) groups. Conclusions: ALPS‐HCC score provides robust predictive power and screening capability for predicting HCC risk in patients with CHB and cACLD.
- 19 February 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (4) , 1376-1377
Response to the Letter Regarding “Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues”
- 19 February 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (4) , 1376-1377
Response to the Letter Regarding “Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues”
- 12 February 2026
- Published by Wiley in Liver International
- Vol. 46 (3) , e70541
Two‐Step MRI and Clinical Model for Detecting At‐Risk Steatohepatitis in Metabolic Liver Disease
Background & Aims: Identifying at‐risk metabolic dysfunction‐associated steatohepatitis (MASH with ≥ stage 2 fibrosis) is critical. While the steatosis‐associated fibrosis estimator (SAFE) score effectively stages significant fibrosis (≥ stage 2 fibrosis) and the MR‐MASH score detects MASH, their combined performance remains unclear. Methods: This two‐part study evaluated serial combinations of non‐invasive tests for at‐risk MASH in clinical and population‐based settings. In part 1, we analysed 286 patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) from an Asian center with biopsy‐proven diagnoses. Four two‐step strategies were compared. In part 2, 495 MASLD patients from the UK Biobank with corrected T1 values were used to validate selected strategies. Results: In part 1, the combination of SAFE followed by the MR‐MASH for at‐risk MASH (strategy A) showed higher accuracy than SAFE followed by FibroScan‐AST (FAST) score and FIB‐4 followed by FAST (87.8% vs. 69.1% and 71.2%, both p < 0.01) and similar misclassification rates (10.1% vs. 11.5% and 11.5%, both p = 0.83). Compared with Fibrosis‐4 followed by magnetic resonance‐based model (strategy B), strategy A had a higher accuracy (88.5% vs. 83.9%, p < 0.01) and a lower misclassification rate (9.1% vs. 12.9%, p < 0.01). In part 2, strategy A maintained a high negative predictive value (99.7%) and showed lower misclassification than strategy B (3.6% vs. 5.7%, p = 0.03), with similar accuracy (82.6% vs. 82.0%, p = 0.74) and indeterminate rates (13.7% vs. 12.3%, p = 0.19). Conclusions: Serial combination of SAFE and MR‐MASH performs well in predicting at‐risk MASH.
- 12 February 2026
- Published by Wiley in Liver International
- Vol. 46 (3) , e70541
Two‐Step MRI and Clinical Model for Detecting At‐Risk Steatohepatitis in Metabolic Liver Disease
Background & Aims: Identifying at‐risk metabolic dysfunction‐associated steatohepatitis (MASH with ≥ stage 2 fibrosis) is critical. While the steatosis‐associated fibrosis estimator (SAFE) score effectively stages significant fibrosis (≥ stage 2 fibrosis) and the MR‐MASH score detects MASH, their combined performance remains unclear. Methods: This two‐part study evaluated serial combinations of non‐invasive tests for at‐risk MASH in clinical and population‐based settings. In part 1, we analysed 286 patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) from an Asian center with biopsy‐proven diagnoses. Four two‐step strategies were compared. In part 2, 495 MASLD patients from the UK Biobank with corrected T1 values were used to validate selected strategies. Results: In part 1, the combination of SAFE followed by the MR‐MASH for at‐risk MASH (strategy A) showed higher accuracy than SAFE followed by FibroScan‐AST (FAST) score and FIB‐4 followed by FAST (87.8% vs. 69.1% and 71.2%, both p < 0.01) and similar misclassification rates (10.1% vs. 11.5% and 11.5%, both p = 0.83). Compared with Fibrosis‐4 followed by magnetic resonance‐based model (strategy B), strategy A had a higher accuracy (88.5% vs. 83.9%, p < 0.01) and a lower misclassification rate (9.1% vs. 12.9%, p < 0.01). In part 2, strategy A maintained a high negative predictive value (99.7%) and showed lower misclassification than strategy B (3.6% vs. 5.7%, p = 0.03), with similar accuracy (82.6% vs. 82.0%, p = 0.74) and indeterminate rates (13.7% vs. 12.3%, p = 0.19). Conclusions: Serial combination of SAFE and MR‐MASH performs well in predicting at‐risk MASH.
- 1 October 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (12) , 2963-2975
Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues
Background: The applicability of the Agile 3+ score to patients with CHB–MASLD receiving antiviral therapy remains unexplored. Our objective was to explore the diagnostic and prognostic performances of the Agile 3+ score in patients with CHB–MASLD. Methods: This retrospective cohort study included consecutively enrolled patients with CHB and concurrent MASLD from 2014 to 2020. In Part 1, we evaluated the performance of the Agile 3+ score in predicting advanced fibrosis. In Part 2, the Agile 3+ score was applied to a follow‐up cohort to assess its correlation with liver‐related events. Results: Among the 2492 patients evaluated by vibration‐controlled transient elastography, 103 patients with CHB and hepatic steatosis were included in the biopsy cohort, and 716 patients were included in the follow‐up cohort. The Agile 3+ score had the highest AUROC of 0.916 for the prediction of advanced fibrosis, outperforming the FIB‐4 score (0.845), NFS (0.838), and APRI (0.726). In predicting liver‐related events (LREs), the AUROC of the Agile 3+ score was also significantly higher (0.795 at 3 years, 0.809 at 5 years, and 0.834 at 8 years) than those of the other noninvasive tests. When the recommended cutoffs (0.451 and 0.679) were applied for MASLD risk stratification, the high‐risk group (HR = 13.61) and intermediate‐risk group (HR = 3.53) had significantly greater risks of LREs than the low‐risk group. Conclusion: In patients with CHB and concurrent MASLD receiving antiviral therapy, the Agile 3+ score effectively identifies advanced fibrosis and predicts LRE risk, supporting its clinical utility in this population.
- 1 October 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (12) , 2963-2975
Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues
Background: The applicability of the Agile 3+ score to patients with CHB–MASLD receiving antiviral therapy remains unexplored. Our objective was to explore the diagnostic and prognostic performances of the Agile 3+ score in patients with CHB–MASLD. Methods: This retrospective cohort study included consecutively enrolled patients with CHB and concurrent MASLD from 2014 to 2020. In Part 1, we evaluated the performance of the Agile 3+ score in predicting advanced fibrosis. In Part 2, the Agile 3+ score was applied to a follow‐up cohort to assess its correlation with liver‐related events. Results: Among the 2492 patients evaluated by vibration‐controlled transient elastography, 103 patients with CHB and hepatic steatosis were included in the biopsy cohort, and 716 patients were included in the follow‐up cohort. The Agile 3+ score had the highest AUROC of 0.916 for the prediction of advanced fibrosis, outperforming the FIB‐4 score (0.845), NFS (0.838), and APRI (0.726). In predicting liver‐related events (LREs), the AUROC of the Agile 3+ score was also significantly higher (0.795 at 3 years, 0.809 at 5 years, and 0.834 at 8 years) than those of the other noninvasive tests. When the recommended cutoffs (0.451 and 0.679) were applied for MASLD risk stratification, the high‐risk group (HR = 13.61) and intermediate‐risk group (HR = 3.53) had significantly greater risks of LREs than the low‐risk group. Conclusion: In patients with CHB and concurrent MASLD receiving antiviral therapy, the Agile 3+ score effectively identifies advanced fibrosis and predicts LRE risk, supporting its clinical utility in this population.
- Open Access
- 9 March 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (1) , 101788
Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease
- 9 March 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (1) , 101788
Open AccessLiver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease
- 18 December 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (3) , 720-730
Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase
Background and Aims: In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes. Methods: We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow‐up) and those who received treatment, following standard AASLD 2018 guidance. Results: The risk of transitioning to the immune active phase over 3, 5, and 10 years was 6.3%, 8.9%, and 14.2%, respectively, for inactive phase patients ( n = 104). For HBeAg‐negative indeterminate phase patients ( n = 194), the risk was significantly higher at 23.0%, 31.9%, and 38.2%, and for HBeAg‐positive indeterminate phase patients ( n = 140), it was 40.4%, 52.0%, and 55.0% ( p < 0.001). Inverse probability of treatment weighting (IPTW) was utilized to balance the groups of treated and untreated indeterminate patients. Following IPTW adjustment, the Kaplan–Meier curve analysis indicates that the risk of HCC and cirrhosis among untreated patients ( n = 294) is higher than that among treated patients ( n = 76), ( p = 0.015 and 0.007, respectively). In the multivariable analysis, antiviral therapy remained an independent predictor of a reduced risk of HCC (aHR 0.128, 95% CI 0.031–0.522, p = 0.005) and cirrhosis (aHR 0.148, 95% CI 0.044–0.496, p = 0.002). Conclusion: The indeterminate phase patients had a high‐risk transition to active phase, and antiviral therapy can reduce the incidence of developing HCC and cirrhosis.
- 18 December 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (3) , 720-730
Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase
Background and Aims: In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes. Methods: We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow‐up) and those who received treatment, following standard AASLD 2018 guidance. Results: The risk of transitioning to the immune active phase over 3, 5, and 10 years was 6.3%, 8.9%, and 14.2%, respectively, for inactive phase patients ( n = 104). For HBeAg‐negative indeterminate phase patients ( n = 194), the risk was significantly higher at 23.0%, 31.9%, and 38.2%, and for HBeAg‐positive indeterminate phase patients ( n = 140), it was 40.4%, 52.0%, and 55.0% ( p < 0.001). Inverse probability of treatment weighting (IPTW) was utilized to balance the groups of treated and untreated indeterminate patients. Following IPTW adjustment, the Kaplan–Meier curve analysis indicates that the risk of HCC and cirrhosis among untreated patients ( n = 294) is higher than that among treated patients ( n = 76), ( p = 0.015 and 0.007, respectively). In the multivariable analysis, antiviral therapy remained an independent predictor of a reduced risk of HCC (aHR 0.128, 95% CI 0.031–0.522, p = 0.005) and cirrhosis (aHR 0.148, 95% CI 0.044–0.496, p = 0.002). Conclusion: The indeterminate phase patients had a high‐risk transition to active phase, and antiviral therapy can reduce the incidence of developing HCC and cirrhosis.
- Open Access
- 6 December 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1419715
Body mass index and waist-to-height ratio effect on mortality in non-alcoholic fatty liver: revisiting the obesity paradox
Purpose: Emerging research indicates that individuals with non-alcoholic fatty liver disease (NAFLD) who carry excess weight have similar or even higher survival rates than their normal-weight counterparts. This puzzling “obesity paradox” may be attributed to underlying biases. To explore this phenomenon, we examined data extracted from the third National Health and Nutrition Examination Survey (NHANES) III, which spanned from 1988-1994.Methods: We specifically targeted participants diagnosed with NAFLD through ultrasound due to fatty liver presence and employed multivariate Cox regression to assess mortality risk associated with body mass index (BMI) and the waist-to-height ratio (WHtR).Results: Over a median follow-up period of 20.3 [19.9-20.7] years, 1832 participants passed away. The study revealed an intriguing “obesity−survival paradox”, in which individuals classified as overweight (HR 0.926, 95% CI 0.925–0.927) or obese (HR 0.982, 95% CI 0.981–0.984) presented reduced mortality risks compared with those categorized as normal weight. However, this paradox vanished upon adjustments for smoking and exclusion of the initial 5-year follow-up period (HR 1.046, 95% CI 1.044–1.047 for overweight; HR 1.122, 95% CI 1.120–1.124 for obesity class I). Notably, the paradox was less pronounced with the WHtR, which was significantly different only in quartile 2 (HR 0.907, 95% CI 0.906–0.909) than in quartile 1, and was resolved after appropriate adjustments. In particular, when BMI and WHtR were considered together, higher levels of adiposity indicated a greater risk of mortality with WHtR, whereas BMI did not demonstrate the same trend (p <0.05).Conclusion: The “obesity paradox” in NAFLD patients can be explained by smoking and reverse causation. WHtR was a better predictor of mortality than BMI.
- 6 December 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1419715
Open AccessBody mass index and waist-to-height ratio effect on mortality in non-alcoholic fatty liver: revisiting the obesity paradox
Purpose: Emerging research indicates that individuals with non-alcoholic fatty liver disease (NAFLD) who carry excess weight have similar or even higher survival rates than their normal-weight counterparts. This puzzling “obesity paradox” may be attributed to underlying biases. To explore this phenomenon, we examined data extracted from the third National Health and Nutrition Examination Survey (NHANES) III, which spanned from 1988-1994.Methods: We specifically targeted participants diagnosed with NAFLD through ultrasound due to fatty liver presence and employed multivariate Cox regression to assess mortality risk associated with body mass index (BMI) and the waist-to-height ratio (WHtR).Results: Over a median follow-up period of 20.3 [19.9-20.7] years, 1832 participants passed away. The study revealed an intriguing “obesity−survival paradox”, in which individuals classified as overweight (HR 0.926, 95% CI 0.925–0.927) or obese (HR 0.982, 95% CI 0.981–0.984) presented reduced mortality risks compared with those categorized as normal weight. However, this paradox vanished upon adjustments for smoking and exclusion of the initial 5-year follow-up period (HR 1.046, 95% CI 1.044–1.047 for overweight; HR 1.122, 95% CI 1.120–1.124 for obesity class I). Notably, the paradox was less pronounced with the WHtR, which was significantly different only in quartile 2 (HR 0.907, 95% CI 0.906–0.909) than in quartile 1, and was resolved after appropriate adjustments. In particular, when BMI and WHtR were considered together, higher levels of adiposity indicated a greater risk of mortality with WHtR, whereas BMI did not demonstrate the same trend (p <0.05).Conclusion: The “obesity paradox” in NAFLD patients can be explained by smoking and reverse causation. WHtR was a better predictor of mortality than BMI.
- Open Access
- 31 October 2024
- Published by MDPI AG in Micromachines
- Vol. 15 (11) , 1341
A Vibrotactile Belt for Measuring Vibrotactile Acuities on the Human Torso Using Coin Motors
Accurate measurement of the vibrotactile acuities of the human torso is the key to designing effective torso-worn vibrotactile displays for healthcare applications such as navigation aids for visually impaired persons. Although efforts have been made to measure vibrotactile acuities, there remains a lack of systematic studies addressing the spatial, temporal, and intensity-related aspects of vibrotactile sensitivity on the human torso. In this work, a torso-worn vibrotactile belt consisting of two crossed coin motor arrays was designed and a psychophysical study was carried out to measure the spatial, temporal, and intensity-related vibrotactile acuities of a set of human subjects wearing the designed belt. The objective parameters of vibrational intensity and the timing latency of the coin motor were also determined before measuring the vibrotactile acuities. The experimental results indicated that the tested coin motor was able to generate a median number of five and six available just-noticeable differences in intensity and duration, respectively. Among the four parameters of vibrational intensity, the perceived intensity was the most relevant to vibrational displacement. The spatial acuities measured as the degree of two-point spatial thresholds (TPTs) showed less individual difference than the distance TPTs. The results from the current work provide valuable guidance for the design of a comfortable torso-worn vibrotactile display using coin motors.
- 31 October 2024
- Published by MDPI AG in Micromachines
- Vol. 15 (11) , 1341
Open AccessA Vibrotactile Belt for Measuring Vibrotactile Acuities on the Human Torso Using Coin Motors
Accurate measurement of the vibrotactile acuities of the human torso is the key to designing effective torso-worn vibrotactile displays for healthcare applications such as navigation aids for visually impaired persons. Although efforts have been made to measure vibrotactile acuities, there remains a lack of systematic studies addressing the spatial, temporal, and intensity-related aspects of vibrotactile sensitivity on the human torso. In this work, a torso-worn vibrotactile belt consisting of two crossed coin motor arrays was designed and a psychophysical study was carried out to measure the spatial, temporal, and intensity-related vibrotactile acuities of a set of human subjects wearing the designed belt. The objective parameters of vibrational intensity and the timing latency of the coin motor were also determined before measuring the vibrotactile acuities. The experimental results indicated that the tested coin motor was able to generate a median number of five and six available just-noticeable differences in intensity and duration, respectively. Among the four parameters of vibrational intensity, the perceived intensity was the most relevant to vibrational displacement. The spatial acuities measured as the degree of two-point spatial thresholds (TPTs) showed less individual difference than the distance TPTs. The results from the current work provide valuable guidance for the design of a comfortable torso-worn vibrotactile display using coin motors.
- 1 July 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (10) , 2169-2181
Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease
Background and Aim: Liver stiffness measurements (LSMs) are promising for monitoring disease progression or regression. We assessed the prognostic significance of dynamic changes in LSM over time on liver‐related events (LREs) and death in patients with chronic hepatitis B (CHB) and compensated advanced chronic liver disease (cACLD).Methods: This retrospective study included 1272 patients with CHB and cACLD who underwent at least two measurements, including LSM and fibrosis score based on four factors (FIB‐4). ΔLSM was defined as [(follow‐up LSM − baseline LSM)/baseline LSM × 100]. We recorded LREs and all‐cause mortality during a median follow‐up time of 46 months. Hazard ratios (HRs) and confidence intervals (CIs) for outcomes were calculated using Cox regression.Results: Baseline FIB‐4, baseline LSM, ΔFIB‐4, ΔLSM, and ΔLSM/year were independently and simultaneously associated with LREs (adjusted HR, 1.04, 95% CI, 1.00–1.07; 1.02, 95% CI, 1.01–1.03; 1.06, 95% CI, 1.03–1.09; 1.96, 95% CI, 1.63–2.35, 1.02, 95% CI, 1.01–1.04, respectively). The baseline LSM combined with the ΔLSM achieved the highest Harrell's C (0.751), integrated AUC (0.776), and time‐dependent AUC (0.737) for LREs. Using baseline LSM and ΔLSM, we proposed a risk stratification method to improve clinical applications. The risk proposed stratification based on LSM performed well in terms of prognosis: low risk (n = 390; reference), intermediate risk (n = 446; HR = 3.38), high risk (n = 272; HR = 5.64), and extremely high risk (n = 164; HR = 11.11).Conclusions: Baseline and repeated noninvasive tests measurement allow risk stratification of patients with CHB and cACLD. Combining baseline and dynamic changes in the LSM improves prognostic prediction.
- 1 July 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (10) , 2169-2181
Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease
Background and Aim: Liver stiffness measurements (LSMs) are promising for monitoring disease progression or regression. We assessed the prognostic significance of dynamic changes in LSM over time on liver‐related events (LREs) and death in patients with chronic hepatitis B (CHB) and compensated advanced chronic liver disease (cACLD).Methods: This retrospective study included 1272 patients with CHB and cACLD who underwent at least two measurements, including LSM and fibrosis score based on four factors (FIB‐4). ΔLSM was defined as [(follow‐up LSM − baseline LSM)/baseline LSM × 100]. We recorded LREs and all‐cause mortality during a median follow‐up time of 46 months. Hazard ratios (HRs) and confidence intervals (CIs) for outcomes were calculated using Cox regression.Results: Baseline FIB‐4, baseline LSM, ΔFIB‐4, ΔLSM, and ΔLSM/year were independently and simultaneously associated with LREs (adjusted HR, 1.04, 95% CI, 1.00–1.07; 1.02, 95% CI, 1.01–1.03; 1.06, 95% CI, 1.03–1.09; 1.96, 95% CI, 1.63–2.35, 1.02, 95% CI, 1.01–1.04, respectively). The baseline LSM combined with the ΔLSM achieved the highest Harrell's C (0.751), integrated AUC (0.776), and time‐dependent AUC (0.737) for LREs. Using baseline LSM and ΔLSM, we proposed a risk stratification method to improve clinical applications. The risk proposed stratification based on LSM performed well in terms of prognosis: low risk (n = 390; reference), intermediate risk (n = 446; HR = 3.38), high risk (n = 272; HR = 5.64), and extremely high risk (n = 164; HR = 11.11).Conclusions: Baseline and repeated noninvasive tests measurement allow risk stratification of patients with CHB and cACLD. Combining baseline and dynamic changes in the LSM improves prognostic prediction.
- Open Access
- 13 June 2024
- Published by Spandidos Publications in Biomedical Reports
- Vol. 21 (2) , 1-12
Proton pump inhibitor use is associated with increased liver steatosis
Despite proton pump inhibitors (PPIs) being generally safe, there are questions about their potential long‑term complications. The present study aimed to investigate the association between PPI therapy and the incidence of hepatic steatosis and liver fibrosis in the outpatient population of the United States. The present study included 7,395 individuals aged ≥20 years who underwent hepatic vibration‑controlled transient elastography (VCTE) examination. The data were obtained from the January 2017 to March 2020 pre‑pandemic National Health and Nutrition Examination Survey. Among the 7,395 adults who were included (mean age, 50.59 years; 3,656 male), 9.8% were prescribed PPIs. Following multivariable adjustment, the use of PPIs was significantly associated with hepatic steatosis [odds ratio (OR), 1.25; 95% confidence interval (CI), 1.02‑1.53]. Prolonged use of PPIs was found to increase the risk of developing hepatic steatosis over time (P=0.006). Sensitivity analyses using different definitions of hepatic steatosis, such as a controlled attenuation parameter ≥285 dB/m (OR, 1.19; CI, 1.01‑1.40), non‑alcoholic fatty liver disease (OR, 1.50; 95% CI, 1.16‑1.93) and metabolic dysfunction‑associated steatotic liver disease (OR, 1.26; 95% CI, 1.05‑1.52), consistently demonstrated an association between PPI prescription and hepatic steatosis. The administration of PPI therapy was linked with hepatic steatosis in US adults, although no significant association was observed with liver stiffness, as determined by VCTE.
- 13 June 2024
- Published by Spandidos Publications in Biomedical Reports
- Vol. 21 (2) , 1-12
Open AccessProton pump inhibitor use is associated with increased liver steatosis
Despite proton pump inhibitors (PPIs) being generally safe, there are questions about their potential long‑term complications. The present study aimed to investigate the association between PPI therapy and the incidence of hepatic steatosis and liver fibrosis in the outpatient population of the United States. The present study included 7,395 individuals aged ≥20 years who underwent hepatic vibration‑controlled transient elastography (VCTE) examination. The data were obtained from the January 2017 to March 2020 pre‑pandemic National Health and Nutrition Examination Survey. Among the 7,395 adults who were included (mean age, 50.59 years; 3,656 male), 9.8% were prescribed PPIs. Following multivariable adjustment, the use of PPIs was significantly associated with hepatic steatosis [odds ratio (OR), 1.25; 95% confidence interval (CI), 1.02‑1.53]. Prolonged use of PPIs was found to increase the risk of developing hepatic steatosis over time (P=0.006). Sensitivity analyses using different definitions of hepatic steatosis, such as a controlled attenuation parameter ≥285 dB/m (OR, 1.19; CI, 1.01‑1.40), non‑alcoholic fatty liver disease (OR, 1.50; 95% CI, 1.16‑1.93) and metabolic dysfunction‑associated steatotic liver disease (OR, 1.26; 95% CI, 1.05‑1.52), consistently demonstrated an association between PPI prescription and hepatic steatosis. The administration of PPI therapy was linked with hepatic steatosis in US adults, although no significant association was observed with liver stiffness, as determined by VCTE.